Ruboxistaurin mesilate hydrate for diabetic retinopathy

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Diabetic retinopathy remains a major worldwide cause of preventable blindness. The β isoform of protein kinase C (PKC) may play an important role in the pathogenesis of this disorder. Ruboxistaurin mesylate hydrate is an orally bioavailable, highly-specific inhibitor of PKC β, which has shown some efficacy in several large, multicenter, randomized clinical trials. The U.S. Food and Drug Administration issued an approvable letter for ruboxistaurin in 2006, but at this time the medication is not available for routine clinical use.

Original languageEnglish (US)
Pages (from-to)269-274
Number of pages6
JournalDrugs of Today
Issue number4
StatePublished - Apr 2009

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Ruboxistaurin mesilate hydrate for diabetic retinopathy'. Together they form a unique fingerprint.

Cite this